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Abstract
Background: Airway remodeling and dysfunction are characteristic features of asthma thought to be caused by
aberrant production of Th2 cytokines. Histamine H4 receptor (H4R) perturbation has previously been shown to
modify acute inflammation and Th2 cytokine production in a murine model of asthma. We examined the ability of
H4R antagonists to therapeutically modify the effects of Th2 cytokine production such as goblet cell hyperplasia
(GCH), and collagen deposition in a sub-chronic model of asthma. In addition, effects on Th2 mediated lung
dysfunction were also determined.
Methods: Mice were sensitized to ovalbumin (OVA) followed by repeated airway challenge with OVA. After
inflammation was established mice were dosed with the H4R antagonist, JNJ 7777120, or anti-IL-13 antibody for
comparison. Airway hyperreactivity (AHR) was measured, lungs lavaged and tissues collected for analysis.
Results: Therapeutic H4R antagonism inhibited T cell infiltration in to the lung and decreased Th2 cytokines IL-13
and IL-5. IL-13 dependent remodeling parameters such as GCH and lung collagen were reduced. Intervention with
H4R antagonist also improved measures of central and peripheral airway dysfunction.
Conclusions: These data demonstrate that therapeutic H4R antagonism can significantly ameliorate allergen
induced, Th2 cytokine driven pathologies such as lung remodeling and airway dysfunction. The ability of H4R
antagonists to affect these key manifestations of asthma suggests their potential as novel human therapeutics.
Background
T h ep a t h o l o g yo fc h r o n i ca s t h m ai sc h a r a c t e r i z e db y
inflammation and remodeling of airway tissues. As a
result of repeated inflammatory insults to the lung,
smooth muscle thickening, mucin secretion and airway
hyperreactivity may develop [1]. The current consensus
as to the etiology of allergic asthma defines it is an aber-
rant T-helper-2 (Th2) type response to environmental
allergens characterized by overproduction of IL-4, IL-5,
and IL-13 which are critical in maintaining an ongoing
IgE-mediated, eosinophilic inflammation [2].
Polarization of naïve Th0 cells to the Th2 and other T
helper sub-sets may be differentially controlled at the
level of the interaction between dendritic cells (DCs)
and antigen-specific T cells. Such interaction can be
directed by a variety of cytokines, chemokines, toll-
ligands and biogenic amines, such as histamine. These
are released at sites where antigen is encountered or
presented and may sequentially modulate the dendritic
cell and subsequent T helper phenotypes [3].
Histamine has long been thought of as an important
mediator of asthma due to its ability to recapitulate
symptoms of asthma, such as bronchoconstriction, and
measured levels being correlated with asthma severity
[4,5]. However, the inefficacy of traditional antihista-
mines, H1 receptor (H1R) antagonists, has lead to the
belief that it is not a viable target for asthma therapy.
Recently, a fourth receptor for histamine, the hista-
mine H4 receptor (H4R) has been identified as a poten-
tial modulator of dendritic cell activation and T cell
polarization and to have a distinct pharmacological pro-
file from H1R[ 6 ] .H 4R is functionally expressed on
many cell types intimately associated with the pathology
of asthma, such as eosinophils, basophils, mast cells,
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[7]. Selective antagonism or gene knockout of H4Rh a s
been demonstrated to diminish allergic lung inflamma-
tion in a mouse model, with specific reduction of Th2-
type cytokines identified in bronchoalveolar lavage fluid
(BALF) and from draining lymph node cultures. Nota-
bly, a profound reduction in Th2 polarization and the
production of the effector Th2 cytokine, IL-13, was
observed [6].
IL-13 is thought to be a critical mediator of allergic
asthma, with genetic and pharmacological evidence sup-
porting its involvement in the development of airway
hyperreactivity (AHR) and the development of chronic
asthma and remodeling phenotypes [8,9]. As such,
numerous approaches to blocking increased IL-13 in
asthma are being evaluated, with emphasis on IL-13
neutralizing antibodies and soluble receptors, but the
identification of oral, small molecule inhibitors of IL-13
would have obvious advantages. We therefore sought to
examine whether the previously reported modulation of
IL-13, and other Th2 cytokines, by H4Ra n t a g o n i s t s
could have a meaningful therapeutic effect on inflamma-
tion, remodeling and airway dysfunction in a sub-
chronic model of allergic lung inflammation in the
mouse
Methods
Mice
BALB/c female mice (6-8 weeks old) were from Charles
River Laboratories. All mice were maintained under spe-
cific pathogen-free conditions and maintained on an
OVA-free diet with free access to food and water. All
experimental animals used in this study were under a
protocol approved by the Institutional Animal Care and
Use Committee of Johnson & Johnson Pharmaceutical
Research & Development, L.L.C.
Rat Anti-Mouse IL-13, CNTO 134, (IgG2a isotype)
was kindly provided by Dr Wil Glass (Centcor Inc, Mal-
vern, PA). JNJ 7777120 was synthesized in the labora-
tories of Johnson & Johnson Pharmaceutical Research &
Development, L.L.C., as previously described [10]. It is a
selective H4R antagonist with a Ki at the mouse H4Ro f
5 Nm [11]. Compound was prepared in solution of 20%
hydroxypropyl- beta- cyclodextran (HPCD), w/v in H2O,
at various concentrations.
Induction of sub-chronic airway inflammation
Mice were immunized intra-peritoneally (i.p.) with 10 μg
OVA (Sigma-Aldrich, St. Louis, MO) in PBS and Inject
Alum (Pierce, Rockford, IL) mixed 1:1 on day 1 and
boosted in the same way on day 8. On day 22, 29, 36,
43, 50, and 57, mice received an intranasal (i.n.) chal-
lenge with 50 μl of PBS or 100 μgo fO V Ai nP B S
(2 mg/ml) under isoflourane anesthesia. Anti-mouse
IL-13 mAb (weekly i.v. 500 μg) or H4Ra n t a g o n i s tJ N J
7777120 (once daily, per os.) treatment was initiated on
d a y3 6o n c ei n f l a m m a t i o nh a da l r e a d yd e v e l o p e da n d
continued through day 58. Agents were administered 1
h prior to each i.n. challenge. Mice were sacrificed on
day 30 (to confirm existing inflammation) or day 59
with a terminal dose of 100 mg/kg sodium pentobarbi-
tal. Serum was obtained from mice and lungs sampled
for inflammation parameters as described below.
Bronchoalveolar lavage (BAL)
Following euthanasia BAL samples were obtained, pro-
cessed and inflammatory cells counted as previously
described [6]. Supernatants were immediately frozen for
subsequent cytokine level analysis by ELISA, as
described below.
T cell proliferation in draining lymph nodes
Peribronchiolar lymph nodes (PBLN) were collected and
pooled. A single cell suspension was prepared and cul-
tured in 96 wells (0.4 million cells/per well) with or
without 100 μg of OVA. After 96 h, 1°C of [
3H] Thymi-
dine was added for 18 hours. Cells were collected on a
filter and [
3H] incorporation quantified. Supernatants
from non-thymidine treated, parallel 96 h cultures were
frozen for subsequent cytokine level analysis by ELISA,
as described below.
Enzyme-Llinked immunosorbent assays (ELISAs)
Cytokines, IL-4, IL-5 and IL-13 levels were determined
in BALF, homogenized lung preparations and in PBLN
culture supernatants by ELISA (R&D Systems, Minnea-
polis, MN). Chemokines CCL3, CCL5 and CCL11 were
similarly measured in lung homogenates. All assays fol-
lowed manufacturers’ directions.
Protein concentration
Tissue was homogenized in PBS using a Fast-Prep
homogenizer (Thermo Savant, Holbrook, NY) and pro-
tein content assayed by BCA assay (Pierce, Rockford, IL)
as per the manufacturers’ instructions.
Total collagen
Free collagen was measured from the supernatants of
homogenized lung tissue in 1 ml PBS using the Sircol,
dye-binding collagen assay kit (Biocolor, Belfast, UK)
according to the manufacturer’s instructions.
Histology
Following BAL, lungs were fixed with 10% formalin
under constant pressure of 15-cm water. After fixation,
lungs were dehydrated and embedded in paraffin by
routine methods parahilar sagittal sections were
obtained. Serial sections were stained with hematoxylin
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blue (counterstained with hematoxylin).
For CD3+ (IHC) staining, slides were deparaffinized
and hydrated in PBS followed by blocking the endogen-
ous peroxide with 3% hydrogen peroxide. To avoid non-
specific reaction with secondary antibody, slides were
pretreated with 10% normal donkey serum before incu-
bation with CD3. The CD3+ primary antibody used in
this study was goat anti-CD3 (2 μg/ml) at a dilution of
1:100 (Santa Cruz Biotechnology, Inc. cat. No. sc-1127
and the secondary antibody used was donkey anti-goat
biotinlated IgG (0.5 μg/ml) (Chemicon International,
Inc. cat. No. AP180B) at a dilution of 1:2000. Normal
goat IgG was used as negative controls. The immunor-
eactivities were visualized by ABC reagents (Vector, Bur-
lingame, cat. No. PK-6100) and diaminobezidine
(Research Genetic, Cat. No. 750118) followed by coun-
terstaining with hematoxylin. CD3+ IHC was quantified
by counting five independent hot fields around the main
segmental bronchus.
For semiquantitative analysis of GCH, sections were
analyzed morphometrically using Simple PCI image ana-
lysis software (Compix Inc, PA). PAS-stained sections
were thresholded by color identification to measure only
the area of mucin content. Mucin content was normal-
ized to the diameter of each airway. At least three sepa-
rate airways from each specimen were measured.
Measurement of airway hyperreactivity
Airway hyperreactivity was induced in mice using a pre-
viously described protocol [6]. Animals received anti-
mouse IL-13 mAb once one day prior to ovalbumin
challenge (i.v. 500 μg) or H4R antagonist JNJ 7777120,
20 mg/kg (b.i.d. p.o.) prior to and 8 hours after each of
four daily challenges. Twenty four hours after the fourth
ovalbumin challenge lung function measurements were
assessed using a computer controlled small animal ven-
tilator (Scireq, Montreal, Canada).
Mice were anesthetized using intra-peritoneal injection
of 100 mg/kg sodium pentobarbital (Euthasol,
ANADA#2). Mechanical respiration on the flexivent was
immediately initiated using a tidal volume of 9 ml/kg at
a rate of 150 breaths/min, with a positive end-expiratory
pressure of 3 cm H2O. Animals were allowed to accli-
mate to the respirator for approximately two minutes to
establish a stable baseline. At this time airway responses
were measured subsequent to aerosolized doses of
methacholine, 0 mg/ml, 25 mg/ml and 50 mg/ml, using
forced oscillation techniques. The resultant pressure and
flow data were fit into a constant phase model as pre-
viously described [12] and analyzed to compare drug-
treated groups with vehicle-treated animals. The mean
of 12 sets of data after each aerosol challenge was ana-
lyzed for individual animals.
Similar to other studies assessing forced oscillatory
mechanics we confined our analysis to: RN (Newtonian
resistance), which assesses the flow resistance of the
conducting airways; G (tissue damping), which reflects
tissue resistance and H (tissue elastance), which reflects
the tissue rigidity [13].
Statistical analysis
One-way analysis of variance, followed by Dunnett’s
multiple comparison test, were performed where indi-
cated. In all cases the P value was calculated based on
the difference between the vehicle treated controls and
respective treatment group in each study. A two-way
analysis of variance, with Bonferroni post-test was per-
formed for airway hyperreactivity measurements. The
error bars shown represent the SEM. In all cases the
experiments were repeated two to three times with simi-
lar results and representative data are shown.
Results
H4R antagonism therapeutically inhibits lung and BAL
Th2 cytokines
T oe x a m i n et h eu t i l i t yo fH 4Ra n t a g o n i s t sd o s e di na
therapeutic regimen we utilized a sub-chronic model of
allergic airway inflammation, [14] and (Fig 1A), in which
dosing of JNJ 7777120 or anti-IL-13 antibody were only
initiated after elicitation of inflammation through two
intranasal ovalbumin challenges in previously sensitized
animals. Confirmation of inflammation by measurement
of airway inflammation and Th2 cytokine induction was
confirmed prior to the commencement of treatment
(Table 1).
After therapeutic treatment with the H4Ra n t a g o n i s t ,
significantly reduced levels of IL-13 were detected com-
pared to vehicle treatment in the BALF (vehicle, 22.3 ±
2.2 pg/ml versus 5 mg/kg H4R, 12.3 ± 2.1 pg/ml P < 0.01)
(Fig 1B), and in the tissue (vehicle, 0.24 ± 0.03 pg/ml ver-
sus 5 mg/kg H4R, 0.12 ± 0.01 pg/μg, P < 0.01) (Fig 1C).
Unfortunately, the nature of the anti-IL-13 antibody
made it impossible to distinguish IL-13 that has been
neutralized from active form using the ELISA assay, so a
comparison of IL-13 levels between vehicle and anti-IL-
13 treated groups was not possible. Levels of IL-5
were also significantly reduced in BALF (vehicle, 23.2 ±
3.4 pg/μg tissue versus 5 mg/kg H4R, 12.3 ± 1.3 pg/μg tis-
sue P < 0.01) and in lung homogenate (vehicle, 0.17 ±
0.04 pg/μgv e r s u s5m g / k gH 4R, 0.05 ± 0.003 pg/μg, P <
0.01) after H4R antagonist treatment. Anti-IL-13 had no
effect on IL-5 levels in either media.
Inhibition of draining lymph node T cell proliferation and
cytokine production
The effect of H4R antagonist treatment on underlying T
cell responses in the model was determined by
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kine production in response to antigen specific stimula-
tion. T cells from both H4R antagonist (20 mg/kg) and
anti-IL-13 treated groups (3035 ± 209 CPM and 3601 ±
117 CPM, P <0.01, respectively versus vehicle, 8316 ±
235 CPM) had decreased proliferation upon re-stimula-
tion with antigen (Fig 2A). In addition, levels of IL-5
and IL-13 in OVA-stimulated culture supernatants were
significantly decreased by H4R antagonist and anti-IL-13
treatment. (Fig 2B). The levels of IL-5 from lymph
nodes of treated animals were below the level of quanti-
fication, which was 15 pg/ml. There was also trend
towards a reduction in IL-4 levels. This last finding may
explain the observed significant reduction in serum ova-
specific IgE after JNJ 7777120 treatment (see figure S1,
additional file 1).
Figure 1 An H4R antagonist therapeutically decreases Th2 associated cytokines from BAL fluid and lung tissue.A nH 4R antagonist
therapeutically decreases Th2 associated cytokines from BAL fluid and lung tissue in a sub-chronic model of allergic airway inflammation. (A)
Model schematic (B) Cell free BAL fluid from vehicle, anti-IL-13 and JNJ 7777120 treated mice (5, 20 and 50 mg/kg) was assayed for the
indicated cytokines by using ELISA. (C) Lung homogenates from the same animals were assayed for cytokine content and corrected for total
protein. n = 8-10. Significance of each treatment group compared to control vehicle-treated animals is as follows: * P < 0.05; ** P < 0.01; ND =
Not determined.
Table 1 Lung Inflammatory parameters at Commencement of Drug Treatment
BALF Cells (×10
6) Lung Cytokines
(pg/μg protein)
WBCs Macs Eos Neuts Lymph IL-5 IL-13
Saline 0.35 ± 0.05 0.35 ± 0.05 0 0 0 BLLOQ 0.01 ± 0.003
OVA 1.85 ± 0.10 0.79 ± 0.06 0.48 ± 0.07 0.57 ± 0.05 0.005 ± 0.004 0.35 ± 0.05 1.24 ± 0.15
Definition of Abbreviations: BALF = bronchoalveolar lavage fluid; BLLOQ = below lower limit of quantification; eos = eosinophils; OVA = ovalbumin; WBCs =
white blood cells. Values represent mean ± SEM
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inflammation
Leukocyte influx into the lung lumen was assessed by
lavage 24 hours after the sixth weekly challenge of
OVA. Eosinophilic inflammation routinely peaks at 48
hours after an allergen challenge in mice, yet we
sampled at 24 hours to allow for the concomitant
assessment of cytokines. Accordingly, a somewhat
mixed eosinophil and neutrophil population was
observed at this time point (Table 1 and Fig 3A). Treat-
ment with the H4R antagonist at 20 mg/kg, initiated on
top of an existing inflammation, significantly reduced
the number of eosinophils in the lavage fluid by 61%
(vehicle, 0.94 ± 0.14 × 10
6 cell/ml versus H4R, 0.37 ±
0.7 × 10
6 cell/ml P < 0.01), however treatment with
anti-IL-13 antibody failed to statistically reduce eosino-
phil influx (Fig. 3A). Similar trends in the reduction of
inflammation were observed in histological sections of
the lung (Fig 3B), and as measured by a blinded patho-
logical score (data not shown). Specific quantification of
CD3 + cell influx from immunohistochemical histology
(Fig 4A) revealed a significant, 49% decrease in OVA
challenged animals when dosed with H4Ra n t a g o n i s t
( v e h i c l e ,7 1±3Tc e l l s / f i e l dv e r s u sH 4R, 36.2 ± 7.5 T
cells/field, P < 0.001) but not when dosed with anti-
IL-13 (Fig 4B). Intranasal administration of PBS to OVA
sensitized animals failed to cause leukocyte recruitment
to the lungs indicating the response to ovalbumin was
antigen specific.
H4R antagonism inhibits T cell attractant chemokines in
lung
The mechanism by which H4R antagonism might reduce
T cell infiltration in to the lung was examined by the
measurement of chemokines in lung homogenates.
From a range of chemokines measured, corrected for
total protein levels, only CCL3, CCL5 and CCL11 were
modulated significantly by H4R antagonism or ani-IL-13
treatment. The potent T cell chemoaatractants, CCL3
(Fig 4C) and CCL5 (Fig 4D) were significantly and dose
dependently attenuated by H4R antagonist treatment,
while CCL11 (eotaxin) was unchanged (Fig 4E). Conver-
sely, anti-IL-13 treatment significantly inhibited CCL11
production, with no effect on CCL3 or CCL5.
A comparable study, in which H4R antagonist, but not
anti-IL-13 was examined revealed an additional dose
dependent and significant inhibition of CCL17 (TARC)
production via H4R antagonism (see figure S2, addi-
tional file 2).
H4R antagonism suppresses goblet cell hyperplasia
In addition to investigating the anti-inflammatory effects
of H4R antagonism, it was important to assess whether
its modulation of Th2 cytokines could have meaningful
effects on allergen induced airway structural changes.
Consequently, an Alcian Blue/PAS stain was used to
identify mucin in the airway epithelium of lung tissue
(Fig 5A) and the mucin area per perimeter airway was
quantified as a measure of goblet cell hyperplasia
(GCH), a major pathological feature of asthma GCH
was significantly increased in ova challenged animals
versus saline controls (Fig 5B). Treatment with H4R
antagonist, 20 mg/kg, significantly reduced GCH (vehi-
cle 3.9 ± 0.35 versus H4R, 1.9 ± 0.22 pix/perimeter air-
way, P < 0.01). In agreement with its central role in
goblet cell differentiation treatment with anti-IL-13
almost completely abolished antigen induced GCH
Figure 2 H4R antagonism decreases antigen-specific lymph
node proliferation and cytokine production. (A) PBLN from
vehicle, JNJ 7777120 (20 mg/kg) and anti-IL-13 treated animals were
cultured with and without the addition of ovalbumin. Proliferation
was determined by the measurement of incorporated
3H thymidine.
(B) Supernatants from parallel lymph node cultures treated with
ovalbumin were assayed for IL-4, IL-5 and IL-13 by ELISA. Lymph
nodes were pooled from 8-10 animals per group and assayed in
quadruplicate. Significance of each treatment group compared to
control vehicle-treated animals is as follows: * P < 0.05, ** P < 0.01,
*** P < 0.001, Ψ < 15 pg/ml, the lower limit of quantification in this
assay.
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perimeter airway, P < 0.01 )
Total lung collagen
Irregular deposition of collagen in the airways is
another physiologically significant marker of Th2 cyto-
kine mediated remodeling. Total collagen and total
free collagen in homogenized lung was measured to
determine the extent of antigen induced airway matrix
remodeling. Treatment with both H4R, 20 mg/kg, and
anti-IL-13 reduced free collagen levels (vehicle, 55.83
±2 . 4μg/mg tissue versus H4R, 44.98 ± 2.7 μg/mg tis-
sue P < 0.01, anti-IL-13, 43.49 μg/mg tissue, P <0 . 0 1 )
(Fig 5C)
H4R antagonism suppresses airway hyperreactivity
Using the sub-chronic airway protocol we did not
observe significant airway hyperreactivity in vehicle
Figure 3 An H4R antagonist inhibits sub-chronic allergic airway inflammation in Balb/C mice. (A) The total number of white blood cells
(WBCs) and differential cell count for eosinophils, monocytes neutrophils and lymphocytes were calculated from BAL fluid collected after the
final OVA challenge. JNJ 7777120 was dosed at 20 mg/kg. n = 8-10 (B) Lung histology, hematoxylin and eosin stain (x200 magnification).
Significance of each treatment group compared to control vehicle-treated animals is as follows: * P < 0.05, ** P < 0.01.
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extent of fibrotic remodeling in the lung (data not
shown). We therefore utilize dap r e v i o u s l yr e p o r t e d
acute model of ovalbumin induced lung inflammation to
study the effects of H4Ra n t a g o n i s ma n dI L - 1 3o n
AHR [6]. To examine airway and peripheral lung dys-
function we measured airway function in ovalbumin
challenged mice upon provocation with the spasmogen,
methacholine (Mch). We used a constant phase model
to separate peripheral and central airway measures.
Newtonian airway resistance, a measure of central air-
way resistance, was significantly increased in the vehicle
animals at both 25 and 50 mg/ml Mch as compared to
PBS challenged animals. Treatment with JNJ 7777120
and anti-IL-13 significantly inhibited the acute broncho-
constriction, measured as a decrease in RN, at both
Figure 4 An H4R antagonist inhibits T cell chemokines and T cell influx in to allergen challenged lungs. Lungs from vehicle, JNJ 7777120
(20 mg/kg) and anti-IL-13 treated animals were sectioned and stained with anti-CD3+ antibody to highlight T cells. (A) Lung histology with CD3
+ stain (400× magnification). n = 4. (B) CD3 + cells were quantified by a blinded observer. (C-E) Lung homogenates from the same animals were
assayed for chemokine content and corrected for total protein. n = 8-10. Significance of each treatment group compared to control vehicle-
treated animals is as follows: * P < 0.05, ** P < 0.01, *** P < 0.001
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(H), a measure of lung stiffness, and tissue damping (G),
a putative measure of peripheral airway obstruction,
were significantly inhibited by treatment of JNJ 7777120
and anti-IL-13 as compared to vehicle control animals
(Fig 6B and 6C).
Discussion
H4R antagonists have previously been shown to have
anti-inflammatory activity when dosed prophylactically
in an acute, mouse model of allergic inflammation [6].
While that study demonstrated a reduction in Th2 cyto-
kine production, no changes in disease relevant Th2 dri-
ven pathologies were reported. In the current study we
demonstrate the ability of an H4Ra n t a g o n i s tt ot h e r a -
peutically modify existing allergic inflammation, and to
attenuate airway remodeling and hyperreactivity.
The model used herein, may be considered to be mast
cell independent, since sensitization protocols involving
co-administration of alum with antigen have been pre-
viously demonstrated as such [6,15]. Consequently,
other cells are considered to be the source of histamine
acting at the H4 receptor in this model, sufficient to
drive Th2 mediated responses. Cells including basophils,
dendritic cells and neutrophil have been shown to
release histamine [6,16,17], with low levels sufficient to
activate the high affinity H4R, and H4Ra n t a g o n i s t s
effective in mast cell deficient animals [6]. Interestingly,
serotonin has also been shown to contribute to airway
inflammation in mast-cell independent models [18] and
has traditionally been viewed as the primary biogenic
amine in rodents. A contribution of histamine and H4R
is now demonstrated and suggests the proposed domi-
nance of serotonin in mice to be predicated on the pre-
vious lack of effects of H1R antagonists in such models
which do not block H4R responses [7].
We firstly demonstrated that the selective H4R antago-
nist, JNJ 7777120, was able to therapeutically reduce
Th2 cytokine levels in diseased lung tissue and in
response to antigen-specific re-stimulation of T cells.
Furthermore, a physiologically significant role for that
reduction was confirmed by the marked attenuation of
IL-13 driven pathologies. Goblet cell hyperplasia and
collagen deposition, classical markers of IL-13 mediated
remodeling in murine models of asthma, [14,19] were
strongly induced by sub-chronic allergic airway inflam-
mation and were fully attenuated by anti-IL-13 antibody
treatment. These effects were recapitulated by H4R
antagonist treatment and in support of a direct relation-
ship of these remodeling parameters to IL-13 levels, the
extent of their amelioration by JNJ 7777120 was propor-
tional to its reduction of IL-13 levels in the tissue.
Figure 5 An H4R antagonist reduces mucus content and free collagen in the airways of allergen challenged lungs. Lungs from vehicle,
JNJ 7777120 (20 mg/kg) and anti-IL-13 treated animals were sectioned and stained with alcian blue/PAS. (A) Lung histology with Alcian blue/
PAS stain. 400× magnification (200× inset) n = 4. (B) Area of mucin staining per length of airway epithelium was calculated using image analysis
software. (C) H4R antagonism inhibits collagen deposition in allergen challenged lungs. Lungs from vehicle, JNJ 7777120 (20 mg/kg) and anti-IL-
13 treated animals were lavaged and resulting BALF was analyzed for free collagen levels. n = 3-8. Significance of each treatment group
compared to control vehicle-treated animals is as follows: ** P < 0.01.
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gic airway dysfunction. Development of airway hyper-
reactivity and hyperresponsiveness to innocuous stimuli
i sad i a g n o s t i ca n dp a t h o l o g i c a lf e a t u r eo fa s t h m at h a t
can be recapitulated in animal models of allergic airway
inflammation, and has been linked to increased airway
IL-13 [20]. In our hands the model of sub-chronic air-
way inflammation that we utilized did not result in a
reproducible increase in airway hyperreactivity, as
reported by others [14]. In contrast to these studies,
which used the dimensionless measure of Penh to mea-
sure AHR, and which in fact may be measuring other
irrelevant respiratory chan g e s[ 2 1 ] ,w eu s e dm o r er e l i -
able forced oscillation techniques to assess airway func-
tion. The absence of airway hyperreactivity observed in
o u rm o d e lm i g h tr e s u l tf r o ma ne x c e s s i v er e m o d e l i n g
and stiffening of the airways, thereby diminishing its
contractile potential. Alternatively other workers have
reported a ‘burning out’ of AHR in such chronic models
[22,23]. Consequently, we utilized another well-
described model to initiate airway hyperreactivity and to
examine the effect of H4R antagonists and anti-IL-13 on
this parameter.
Using this model, a robust hyperreactivity was demon-
strated in vehicle treated mice as indicated by an
increase in central and peripheral airways resistance. A
corresponding increase in peripheral lung stiffness (ela-
stance) was also measured in vehicle treated animals.
All of these parameters were blocked both by H4R
antagonism and anti-IL-13 treatment. Previous research
has highlighted the importance of IL-13 in controlling
airway hyperresponsiveness in mice [8,20]. Several
Figure 6 H4R antagonism inhibits airway hyperreactivity and dysfunction in allergen challenged lungs. Animals treated with vehicle, JNJ
7777120 (20 mg/kg b.i.d) and anti-IL-13 around an acute(4 ×) ovalbumin challenge were anesthetized 24 h after the last challenge and lung
function measured via a small animal ventilator by forced oscillation techniques. Methacholine dose response relationships were obtained for (A)
central airway resistance, (B) tissue stiffness and (C) tissue damping. Each plotted value reflects the mean values for each group of mice (n = 6-
10/group). Each animal’s value reflects the mean of 12 sets of data captured over a 3-minute span after each aerosol challenge was analyzed for
individual animals. Significance of each treatment group compared to control vehicle-treated animals is as follows: * P < 0.05, ** P < 0.01, *** P
< 0.001
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dent airway structural cells, and not a secondary effect
due to recruitment of inflammatory cells [8,20]. Conse-
quently, we reproduced results that supported this
observation since anti-IL-13 treatment resulted in a
complete abolishment of airway hyperreactivity, with no
effect on airway inflammation.
Whilst these effects on goblet cell hyperplasia, col-
lagen deposition and airway hyperreactivity supported
the premise that H4R may modulate chronic remodeling
through modulation of IL-13 production, other anti-
inflammatory effects of H4Ra n t a g o n i s ma p p e a rt ob e
independent of the reduction in IL-13, since they were
not recapitulated by anti-IL-13 treatment. Notably,
whilst H4R antagonists were able to inhibit eosinophil
and T cell influx into the airways, anti-IL-13 treatment
did not cause a significant attenuation of these cell
types. The effect on eosinophilic inflammation may in
part be due to the fact that IL-5 in the airways, as mea-
sured in BALF and in lung homogenate, was reduced in
H4R antagonist treated animals, whereas anti-IL-13
treatment had little effect. Conversely, anti-IL-13 did
reduce eotaxin (CCL11) levels, whereas H4R treatment
did not, perhaps suggesting a redundant role for eotaxin
in this particular model.
The lower levels of IL-5 and IL-13 observed in the
lung are likely a result of decreased recruitment of T
cells since CD3+ T cells were seen to be reduced in the
lung after H4R antagonist treatment, but not by anti-IL-
13 treatment. The effect on T cell influx in to the lung
may relate to the observed reduction in CCL3 and
CCL5 in lung tissue which may act at both CCR1 and
CCR5 to modulate T cell recruitment in to the allergic
lung [24,25]. Reduction of the CCR4 ligand, CCL17 by
H4R antagonist in a comparable study (additional data)
also suggests a direct inhibition of CCR4 + Th2 cells, a
sub-population implicated in asthma pathogenesis [26].
CCR1 positive T cells have been shown to be associated
with IL-13 release [24] and Th2 cells are known to be
the main source of IL-5 in allergic airway inflammation
[27]. Of additional interest, H4R has been implicated in
direct recruitment of T cell subsets to the lung [28] and
in the release of other T cell chemoattractants such as
IL-16 [29].
IL-5 and IL-13 levels in the tissue may also be reduced
by a direct effect on Th2 cell cytokine elaboration. Indeed
antigen restimulation of lymphocytes from H4Ra n t a g o -
nist treated animals led to lower levels of both cytokines.
This is likely related to the previously reported modula-
tion of Th2 polarization by H4R antagonists [6]. In this
previous study decreases in IL-4, IL-5 and IL-13 were
also demonstrated in ovalbumin stimulated lymph node
cultures from H4R antagonist treated or H4Rd e f i c i e n t
mice, despite any effect on proliferation. This effect on
Th2 cytokines, via a modulation of Th2 activation, may
result from a role of H4R in the Th2 priming capability of
dendritic cells [6]. The exact mechanism for this is as yet
unknown, but reduced levels of pro-Th2 cytokines such
as IL-4 and IL-6 may explain the reduction in down-
stream Th2 polarization. Indeed, a functionally relevant
r e d u c t i o ni nI L - 4w a ss u g g e s t e db ya no b s e r v e dd e c r e a s e
in antigen-specific IgE observed with H4Ra n t a g o n i s t
treatment.
In contrast to findings in the acute model of asthma
[6], in the sub-chronic model reported herein, antigen
specific lymph node proliferation was attenuated after
therapeutic treatment with JNJ 7777120. This may result
from the continued activation of memory T cells in the
more chronic setting, and its progressive attenuation
under H4R blockade. One explanation of this may be
the reduction in IL-4 production following restimulation
seen here and in the previous model [6]. Reduction in
IL-4 levels would likely suggest that subsequent Th0 to
Th2 polarization of new effectors cells with each antigen
challenge would be disrupted. In addition, other workers
have described an H4R dependent reduction in Th1 pro-
moting cytokine IL-12 production from human dendritic
cells that may contribute to this effect [30]. Therefore, a
possible reduction in antigen-specific Th2 cells might
therefore be possible with chronic dosing of an H4R
antagonist in a disease setting where individuals are
continually exposed to allergen.
The inefficacy of anti-IL-13 on lung inflammation and
tissue IL-5 levels reported here is in contrast to other
reports in similar models where IL-5 was reduced in
BALF by an IL-13 vaccine approach [19] or in lung
homogenates, with an anti-IL-13 antibody [14]. Never-
theless our data is consistent with previous reports
showing that over expression of IL-13 did not alter IL-5
expression in mouse lung [9], nor was it affected by IL-
13 genetic deficiency in a mouse asthma model [20].
To put our findings into a clinical context, whilst the
targeting of single cytokines, such as IL-4 [31,32] or IL-
5 [33-35], has repeatedly failed to show meaningful clin-
ical benefit in broad asthma populations a recent report
has highlighted the efficacy of an inhaled, dual IL-4/IL-
13 receptor blocker [36]. Consequently, a broader
approach to inhibiting Th2 cytokine production, as pos-
sible with H4R antagonists and other small molecule
inhibitors of Th2 cell polarization, may prove beneficial.
Provocatively, suplatast tosilate, a small molecule modu-
lator of dendritic cell function and of Th2 cytokine pro-
duction, working through an, as yet, unknown
mechanism, has demonstrated efficacy in asthmatic indi-
viduals, [37,38] with reported diminishment of IL-4 and
IL-13 producing cells and concomitant goblet cell
hyperplasia [39]. H4R antagonists share these properties,
at least in mouse models examined so far.
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Therapeutic treatment with an H4R antagonist can inhi-
bit Th2 driven pathologies such as lung remodeling in a
model of sub-chronic asthma and, in addition, can
improve airway dysfunction. These observations, in con-
junction with the previously reported direct effects of
H4R perturbation on mast cell and eosinophil function
again reiterate the potential importance of histamine in
asthma and suggest the utility of H4R antagonists as
novel therapeutics in allergic respiratory disease.
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